1. Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001 
Eiki Ichihara, MD, PhD, Katsuyuki Hotta, MD, PhD, Naoyuki Nogami, MD, PhD, Shoichi Kuyama, MD, PhD, Daizo Kishino, MD, PhD, Masanori Fujii, MD, PhD, Toshiyuki Kozuki, MD, PhD, Masahiro Tabata, MD, PhD, Daijiro Harada, MD, PhD, Kenichi Chikamori, MD, PhD, Keisuke Aoe, MD, PhD, Hiroshi Ueoka, MD, PhD, Shinobu Hosokawa, MD, PhD, Akihiro Bessho, MD, PhD, Akiko Hisamoto-Sato, MD, PhD, Toshio Kubo, MD, PhD, Isao Oze, MD, PhD, Nagio Takigawa, MD, PhD, Mitsune Tanimoto, MD, PhD, Katsuyuki Kiura, MD, PhD 
Journal of Thoracic Oncology 
Volume 10, Issue 3, Pages (March 2015)
DOI: /JTO
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
A. Progression-free survival (PFS) curve for the 42 patients. B. PFS curves according to epidermal growth factor receptor (EGFR) mutation status. Solid line, EGFR exon 19 deletion; dashed line, exon 21 L858R mutation. Gray lines represent 95% confidence intervals.
Journal of Thoracic Oncology  , DOI: ( /JTO )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
Overall survival curve for the 42 patients. Gray lines represent 95% confidence intervals.
Journal of Thoracic Oncology  , DOI: ( /JTO )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions